Accurate dose calibrator activity measurement of 90Y-ibritumomab tiuxetan

被引:0
|
作者
Siegel, JA
Zimmerman, BE
Kodimer, K
Dell, MA
Simon, WE
机构
[1] Nucl Phys Enterprises, Wellington, FL 33414 USA
[2] Natl Inst Stand & Technol, Gaithersburg, MD 20899 USA
[3] Cardinal Hlth Nucl Pharm Serv, Woodland Hills, CA USA
[4] Capintec Inc, Ramsey, NJ USA
[5] Sun Nucl Corp, Melbourne, FL USA
关键词
Y-90; measurement; dose calibrator; ibritumomab tiuxetan;
D O I
暂无
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
This investigation examined the accuracy of dose calibrator activity measurement of the beta-emitting radiopharmaceutical Y-90-ibritumomab tiuxetan. Methods: Five different facilities independently measured Y-90 in a 10-mL syringe geometry with 30 dose calibrator models from 3 different manufacturers. The activities ranged from 81.4 MBq (2.2 mCi) to 1,406 MBq (38 mCi) over the volume range of 3-9 mL. Results: The mean dial settings for Y-90 measurement were 375, 51 x 10, and 897 x 100 for Atomlab, CRC, and Mark V dose calibrators, respectively. The maximum volume dependence was 0.28%/mL. Conclusion: This study demonstrated that when measuring all volumes of Y-90-ibritumomab tiuxetan activity prescriptions, only a single dial setting for a given manufacturer's dose calibrator is required for accurate measurements. Volume corrections are not necessary. For best accuracy, an individually determined dial value should be used.
引用
收藏
页码:450 / 454
页数:5
相关论文
共 50 条
  • [1] Radioimmunotherapy with 90Y-Ibritumomab Tiuxetan
    Brockmann, H
    Biersack, HJ
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2006, 131 (09) : 438 - 440
  • [2] Radioimmunotherapy with 90Y-ibritumomab tiuxetan (Zevalin®)
    Bello, P.
    Almoguera, M. I.
    Pajares, M.
    Olivas, C.
    Lapena, L.
    Freire, J. M.
    REVISTA ESPANOLA DE MEDICINA NUCLEAR, 2010, 29 (01): : 50 - 52
  • [3] Occupational Dose Measurements For Personnel Performing 90Y-Ibritumomab Tiuxetan Administration
    Law, M.
    Ng, S.
    Liu, R.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2009, 36 : S267 - S268
  • [4] A single dose calibrator dial setting accurately measures 90Y ibritumomab tiuxetan activity.
    Siegel, JA
    Zimmerman, BE
    Kodimer, K
    Dell, MA
    Simon, WE
    JOURNAL OF NUCLEAR MEDICINE, 2003, 44 (05) : 317P - 317P
  • [5] Estimates of Radiation-Absorbed Dose to Kidneys in Patients Treated with 90Y-Ibritumomab Tiuxetan
    Baechler, Sebastien
    Hobbs, Robert F.
    Prideaux, Andrew R.
    Recordon, Melanie
    Bischof-Delaloye, Angelika
    Sgouros, George
    CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2008, 23 (05) : 633 - 639
  • [6] Radioimmunotherapy for NHL:: Experience of 90Y-ibritumomab tiuxetan in clinical practice
    Hagenbeek, A
    LEUKEMIA & LYMPHOMA, 2003, 44 : S37 - S47
  • [7] Experience with 90Y-ibritumomab tiuxetan for relapsed classical Hodgkin lymphoma
    Younes, A.
    Wong, F.
    ANNALS OF ONCOLOGY, 2009, 20 (06) : 1147 - 1148
  • [8] Efficacy of 90Y-Ibritumomab Tiuxetan in marginal-zone lymphoma (MZL)
    Vanazzi, Anna
    Ferrucci, Pier Francesco
    Grana, Chiara
    Pruneri, Giancarlo
    Crosta, Cristiano
    Pinto, Antonello
    Chinol, Marco
    Paganelli, Giovanni
    Martinelli, Giovanni
    BLOOD, 2007, 110 (11) : 196B - 197B
  • [9] Imaging of the distribution of 90Y-ibritumomab tiuxetan in bone marrow and comparison with pathology
    Coulot, Jeremy
    Camara-Clayette, Valerie
    Ricard, Marcel
    Lavielle, Frederic
    Velasco, Valerie
    Drusch, Francoise
    Bosq, Jacques
    Schlumberger, Martin
    Ribrag, Vincent
    CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2007, 22 (05) : 665 - 671
  • [10] 90Y-Ibritumomab Tiuxetan Therapy evaluated by PET: Experience on 53 Patients
    Santi, I.
    Maffione, A.
    Ambrosini, V.
    Rubello, D.
    Castellucci, P.
    Montini, G.
    Stefoni, V.
    Nanni, C.
    Pizzocaro, C.
    Savelli, G.
    Zinzani, P.
    Fanti, S.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2008, 35 : S174 - S174